UBI集團訊息
President of United BioPharma, Dr. Mei Jun Liao, is invited to the 5th Biologics World Taiwan as The Invited Speaker
Dr. Liao received her Ph.D. in physical Biochemistry from Yale University and joined UBP in 2014, with extensive experience in the biopharmaceutical industry. Dr. Liao has led UBP to achieve considerable milestones. For example, UBP is launching the international phase III clinical trial for its innovative AIDS therapeutic candidate UB-421.
UBP processes an integrated-advanced R&D platform and many new drugs with significant market potential. Moreover, the new industrial-scale protein API facility will be completed in April this year. UBP strives to file new drug applications and expand international business and strategic alliances.
About United BioPharma (6471)
United BioPharma (UBP) was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnered with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs to improve the health of mankind.
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.